GlassScriptPhysician profile
Bhaskar S Palekar
NPI 1750329322
$21,735.28
in general payments reported to CMS, 2019-2025
73 companies · $3,162 in 2025
The $3,162 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,681 · 2020: $1,630 · 2021: $4,721 · 2022: $3,133 · 2023: $2,611 · 2024: $2,797 · 2025: $3,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,570.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,728.78 | 2019-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $2,546.52 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $2,529.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,123.76 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $1,109.96 | 2019-2025 | |
| Medtronic, INC. | $1,103.92 | 2021-2025 | Azure Xt Dr Mri Surescan, Corevalve Evolut R, Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,059.19 | 2019-2025 | Jardiance |
| Daiichi Sankyo INC. | $769.60 | 2019-2025 | Injectafer |
| Pfizer INC. | $590.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $469.50 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $468.39 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $446.76 | 2019-2023 | |
| Abbott Laboratories | $436.24 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $388.39 | 2020-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $365.37 | 2019-2025 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhaskar Palekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.